Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 2/3, Open-Label, Multi-center Study of the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of A Long-acting Human Growth Hormone (Somavaratan, VRS-317) in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD)

Next Previous
Trial Profile

A Randomized, Phase 2/3, Open-Label, Multi-center Study of the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of A Long-acting Human Growth Hormone (Somavaratan, VRS-317) in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD)

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 27 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somavaratan (Primary)
  • Indications Growth disorders; Somatotropin deficiency
  • Focus Registrational; Therapeutic Use
  • Sponsors Versartis

    • Most Recent Events

    • 26 Oct 2017 Status changed from recruiting to discontinued, according to a Versartis media release.
    • 27 Apr 2017 According to a Versartis media release, the company anticipates to complete enrollment in the phase III portion of the trial in the second half of 2017.
    • 04 Apr 2017 Results (n=48) comapring PK/PD properties of somavaratan in USA and Japan prepubertal children using patient data from VERTICAL and J14VR5 trials, presented at The 99th Annual Meeting of the Endocrine Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top